Literature DB >> 33993248

Harmonization of LC-MS/MS Measurements of Plasma Free Normetanephrine, Metanephrine, and 3-Methoxytyramine.

Mirko Peitzsch1, Talia Novos2, Denise Kaden1, Max Kurlbaum3, Antonius E van Herwaarden4, Daniel Müller5, Jo Adaway6, Eric Grouzmann7, Brett McWhinney8, Kirsten Hoad9, Gerald Woollard10, Ido Kema11, Christopher Boot12, Martin Fassnacht3, Fred Sweep4, Tze P Loh13, Andrea R Horvath2, Graeme Eisenhofer1,14.   

Abstract

BACKGROUND: Plasma-free normetanephrine and metanephrine (metanephrines) are the recommended biomarkers for testing of pheochromocytoma and paraganglioma (PPGL). This study evaluated the status of harmonization of liquid chromatography-tandem mass spectrometry-based measurements of plasma metanephrines and methoxytyramine and clinical interpretation of test results.
METHODS: 125 plasma samples from patients tested for PPGLs were analyzed in 12 laboratories. Analytical performance was also assessed from results of a proficiency-testing program. Agreement of test results from different laboratories was assessed by Passing-Bablok regression and Bland-Altman analysis. Agreement in clinical test interpretation based on laboratory specific reference intervals was also examined.
RESULTS: Comparisons of analytical test results by regression analysis revealed strong correlations for normetanephrine and metanephrine (R ≥ 0.95) with mean slopes of 1.013 (range 0.975-1.078), and 1.019 (range 0.963-1.081), and intercepts of -0.584 (-53.736 to 54.790) and -3.194 (-17.152 to 5.933), respectively. The mean bias between methods was 1.2% (-11.6% to 16.0%) for metanephrine and 0.1% (-18.0% to 9.5%) for normetanephrine. Measurements of 3-methoxytyramine revealed suboptimal agreement between laboratories with biases ranging from -32.2% to 64.0%. Interrater agreement in test interpretation was >94% for metanephrine and >84% for normetanephrine; improvements in interrater agreement were observed with use of harmonized reference intervals, including age-specific cut-offs for normetanephrine.
CONCLUSIONS: Analytical methods for metanephrines are well harmonized between laboratories. However, the 16% disagreement in test interpretation for normetanephrine suggests use of suboptimal method-dependent reference intervals for clinical decision-making for this metabolite. Improved analytical methods and reference interval harmonization are particularly required for 3-methoxytyramine. © American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  LC-MS/MS; harmonization; metanephrines; paraganglioma; pheochromocytoma; standardization

Mesh:

Substances:

Year:  2021        PMID: 33993248     DOI: 10.1093/clinchem/hvab060

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine.

Authors:  Susan Richter; Bei Qiu; Mirthe Ghering; Carola Kunath; Georgiana Constantinescu; Charlotte Luths; Christina Pamporaki; Nicole Bechmann; Leah Meuter; Aleksandra Kwapiszewska; Timo Deutschbein; Svenja Nölting; Mirko Peitzsch; Mercedes Robledo; Aleksander Prejbisz; Karel Pacak; Volker Gudziol; Henri J L M Timmers; Graeme Eisenhofer
Journal:  Endocr Relat Cancer       Date:  2022-03-21       Impact factor: 5.678

2.  Commutability Assessment of Processed Human Plasma Samples for Normetanephrine and Metanephrine Measurements Based on the Candidate Reference Measurement Procedure.

Authors:  Yuhang Deng; Qingxiang Liu; Zhenni Liu; Haijian Zhao; Weiyan Zhou; Chuanbao Zhang
Journal:  Ann Lab Med       Date:  2022-09-01       Impact factor: 4.941

Review 3.  Biochemical Diagnosis of Catecholamine-Producing Tumors of Childhood: Neuroblastoma, Pheochromocytoma and Paraganglioma.

Authors:  Graeme Eisenhofer; Mirko Peitzsch; Nicole Bechmann; Angela Huebner
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-26       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.